Non-invAsive VentIlation for early General wArd respiraTory failurE (NAVIGATE): A multicenter randomized controlled study. Protocol and statistical analysis plan
التفاصيل البيبلوغرافية
العنوان:
Non-invAsive VentIlation for early General wArd respiraTory failurE (NAVIGATE): A multicenter randomized controlled study. Protocol and statistical analysis plan
Cabrini, L, Brusasco, C, Roasio, A, Corradi, F, Nardelli, P, Filippini, M, Cotticelli, V, Belletti, A, Ferrara, L, Antonucci, E, Baiardo Redaelli, M, Lattuada, M, Colombo, S, Olper, L, Ponzetta, G, Ananiadou, S, Monti, G, Severi, L, Maj, G, Giardina, G, Biondi-Zoccai, G, Benedetto, U, Gemma, M, Cavallero, S S M, Hajjar, L A, Zangrillo, A, Bellomo, R & Landoni, G 2019, ' Non-invAsive VentIlation for early General wArd respiraTory failurE (NAVIGATE) : A multicenter randomized controlled study. Protocol and statistical analysis plan ', Contemporary Clinical Trials, vol. 78, pp. 126-132 . https://doi.org/10.1016/j.cct.2019.02.001
ObjectiveFew randomized trials have evaluated the use of non-invasive ventilation (NIV) for early acute respiratory failure (ARF) in non-intensive care unit (ICU) wards. The aim of this study is to test the hypothesis that early NIV for mild-moderate ARF in non-ICU wards can prevent development of severe ARF.DesignPragmatic, parallel group, randomized, controlled, multicenter trial.SettingNon-intensive care wards of tertiary centers.PatientsNon-ICU ward patients with mild to moderate ARF without an established indication for NIV.InterventionsPatients will be randomized to receive or not receive NIV in addition to best available care.Measurements and main resultsWe will enroll 520 patients, 260 in each group. The primary endpoint of the study will be the development of severe ARF. Secondary endpoints will be 28-day mortality, length of hospital stay, safety of NIV in non-ICU environments, and a composite endpoint of all in-hospital respiratory complications.ConclusionsThis trial will help determine whether the early use of NIV in non-ICU wards can prevent progression from mild-moderate ARF to severe ARF.
